Registro:

Referencias:

• World Health Organization, Global Tuberculosis Report (2015), http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf, Available from: (Accessed 1 October 2017); Zumla, A., Chakaya, J., Centis, R., D'Ambrosio, L., Mwaba, P., Bates, M., Tuberculosis treatment and management–an update on treatment regimens, trials, new drugs, and adjunct therapies (2015) Lancet Respir Med, 3 (3), pp. 220-234
• Daley, C.L., Caminero, J.A., Management of multidrug resistant tuberculosis (2013) Semin Respir Crit Care Med, 34 (1), pp. 44-59
• Casali, N., Nikolayevskyy, V., Balabanova, Y., Harris, S.R., Ignatyeva, O., Kontsevaya, I., Evolution and transmission of drug-resistant tuberculosis in a Russian population (2014) Nat Genet, 46 (3), pp. 279-286
• Acosta, C.D., Dadu, A., Ramsay, A., Dara, M., Drug-resistant tuberculosis in Eastern Europe: challenges and ways forward (2014) Public Health Action, 4, pp. S3-12
• Balabanova, Y., Ignatyeva, O., Fiebig, L., Riekstina, V., Danilovits, M., Jaama, K., Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference? (2016) Thorax, 71, pp. 854-861
• Skrahina, A., Hurevich, H., Zalutskaya, A., Sahalchyk, E., Astrauko, A., Hoffner, S., Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors (2013) Bull World Health Organ, 91 (1), pp. 36-45
• Skrahina, A., Hurevich, H., Zalutskaya, A., Sahalchyk, E., Astrauko, A., van Gemert, W., Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk (2012) Eur Respir J, 39 (6), pp. 1425-1431
• UNAIDS, AIDS by the numbers (2015), http://www.unaids.org/sites/default/files/media_asset/AIDS_by_the_numbers_2015_en.pdf, WORLD AIDS DAY; Available from: (Accessed 1 October 2017); Yablonskii, P.K., Vizel, A.A., Galkin, V.B., Shulgina, M.V., Tuberculosis in Russia. Its history and its status today (2015) Am J Respir Crit Care Med, 191 (4), pp. 372-376
• DeHovitz, J., Uuskula, A., El-Bassel, N., The HIV epidemic in Eastern Europe and Central Asia (2014) Curr HIV/AIDS Rep, 11 (2), pp. 168-176
• Efsen, A.M., Schultze, A., Post, F.A., Panteleev, A., Furrer, H., Miller, R.F., Major challenges in clinical management of TB/HIV coinfected patients in Eastern Europe compared with Western Europe and Latin America (2015) PLoS ONE, 10 (12). , e0145380
• Mocroft, A., Lundgren, J., Antinori, A., Monforte, A., Brannstrom, J., Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013 (2015) Euro Surveill, 20 (47)
• Post, F.A., Grint, D., Werlinrud, A.M., Panteleev, A., Riekstina, V., Malashenkov, E.A., Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe (2014) J Infect, 68 (3), pp. 259-263
• Podlekareva, D.N., Efsen, A.M., Schultze, A., Post, F.A., Skrahina, A.M., Panteleev, A., Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study (2016) Lancet HIV, 3 (3), pp. e120-31
• World Health Organization, Guidelines for the programmatic management of drug-resistant tuberculosis (2011), http://apps.who.int/iris/bitstream/10665/44597/1/9789241501583_eng.pdf, update; Available from: (Accessed 1 October 2017); Gunther, G., Gomez, G.B., Lange, C., Rupert, S., van Leth, F., Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey (2015) Eur Respir J, 45 (4), pp. 1081-1088
• Lange, C., Abubakar, I., Alffenaar, J.W., Bothamley, G., Caminero, J.A., Carvalho, A.C., Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement (2014) Eur Respir J, 44 (1), pp. 23-63
• World Health Organization, WHO treatment guidelines for drug-resistant tuberculosis (2016), http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf, update; Available from: (Accessed 1 October 2017); Conradie, F., Diacon, A., Everitt, D., Mendel, C., Niekerk, C., Howell, P., The NIX-TB Trial Of Pretomanid, Bedaquiline And Linezolid To TreaT XDR-TB (2017), Abstract number 80LB. Oral presentation from Conference on Retroviruses and Opportunistic Infections (CROI); Ahuja, S.D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J.N., Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients (2012) PLoS Med, 9 (8), p. e1001300
• Abubakar, I., Zignol, M., Falzon, D., Raviglione, M., Ditiu, L., Masham, S., Drug-resistant tuberculosis: time for visionary political leadership (2013) Lancet Infect Dis, 13 (6), pp. 529-539
• Strobe Group, Strobe statement (2009), http://strobe-statement.org/index.php?id=strobe-home, Available from: (Accessed 1 October 2017); World Health Organization, Treatment of tuberculosis guidelines fourth edition (2010), http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf?ua=1&ua=1, Available from: (Accessed 1 October 2017); Xie, Y.L., Chakravorty, S., Armstrong, D.T., Hall, S.L., Via, L.E., Song, T., Evaluation of a rapid molecular drug-susceptibility test for tuberculosis (2017) N Engl J Med, 377 (11), pp. 1043-1054
• Zignol, M., Dean, A.S., Alikhanova, N., Andres, S., Cabibbe, A.M., Cirillo, D.M., Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project (2016) Lancet Infect Dis, 16 (10), pp. 1185-1192
• Gunther, G., van Leth, F., Altet, N., Dedicoat, M., Duarte, R., Gualano, G., Beyond multidrug-resistant tuberculosis in Europe: a TBNET study (2015) Int J Tuberc Lung Dis, 19 (12), pp. 1524-1527
• Podlekareva, D.N.S.A., Panteleev, A., Skrahina, A.M., Miro, J.M., Rakhmanova, A., Furrer, H., One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid- susceptible tuberculosis in Eastern Europe, Western Europe and Latin America (2016), and the; TB:HIV study in EuroCoord#; Accepted for publication in AIDS; Ahmad Khan, F., Gelmanova, I.Y., Franke, M.F., Atwood, S., Zemlyanaya, N.A., Unakova, I.A., Aggressive regimens reduce risk of recurrence after successful treatment of MDR-TB (2016) Clin Infect Dis, 63, pp. 214-220
• Franke, M.F., Appleton, S.C., Mitnick, C.D., Furin, J.J., Bayona, J., Chalco, K., Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence (2013) Clin Infect Dis, 56 (6), pp. 770-776
• Velasquez, G.E., Becerra, M.C., Gelmanova, I.Y., Pasechnikov, A.D., Yedilbayev, A., Shin, S.S., Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death (2014) Clin Infect Dis, 59 (1), pp. 9-15
• Mansfeld, M., Skrahina, A., Shepherd, L., Schultze, A., Panteleev, A.M., Miller, R.F., Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe (2015) HIV Med, 16 (9), pp. 544-552
• Abdool Karim, S.S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A., Timing of initiation of antiretroviral drugs during tuberculosis therapy (2010) N Engl J Med, 362 (8), pp. 697-706
• Blanc, F.X., Sok, T., Laureillard, D., Borand, L., Rekacewicz, C., Nerrienet, E., Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis (2011) N Engl J Med, 365 (16), pp. 1471-1481
• Group, I.S.S., Lundgren, J.D., Babiker, A.G., Gordin, F., Emery, S., Grund, B., Initiation of antiretroviral therapy in early asymptomatic HIV infection (2015) N Engl J Med, 373 (9), pp. 795-807
• Havlir, D.V., Kendall, M.A., Ive, P., Kumwenda, J., Swindells, S., Qasba, S.S., Timing of antiretroviral therapy for HIV-1 infection and tuberculosis (2011) N Engl J Med, 365 (16), pp. 1482-1491
• UNAIDS, 90-90-90 An ambitious treatment target to help end the AIDS epidemic (2014), http://www.unaids.org/en/resources/documents/2017/90-90-90, Available from: (Accessed 1 October 2017); Satti, H., McLaughlin, M.M., Hedt-Gauthier, B., Atwood, S.S., Omotayo, D.B., Ntlamelle, L., Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho (2012) PLoS ONE, 7 (10). , e46943
• Shin, S.S., Modongo, C., Boyd, R., Caiphus, C., Kuate, L., Kgwaadira, B., High treatment success rates among HIV-infected multidrug-resistant tuberculosis patients after expansion of antiretroviral therapy in Botswana, 2006–2013 (2017) J Acquir Immune Defic Syndr, 74, pp. 65-71
• Umanah, T., Ncayiyana, J., Padanilam, X., Nyasulu, P.S., Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa (2015) BMC Infect Dis, 15, p. 478
• Isaakidis, P., Casas, E.C., Das, M., Tseretopoulou, X., Ntzani, E.E., Ford, N., Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis (2015) Int J Tuberc Lung Dis, 19 (8), pp. 969-978
• Podlekareva, D.N., Panteleev, A.M., Grint, D., Post, F.A., Miro, J.M., Bruyand, M., Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe (2014) Eur Respir J, 43 (1), pp. 166-177
• Morozova, O., Dvoryak, S., Altice, F.L., Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine (2013) Int J Drug Policy, 24 (6), pp. e91-8

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------